MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma
| Autor: | Gamal Shiha, Ibrahim Abd El-Magid, S. Seif, Osama Elbaz El Agroudy, Hazem Hakim Elmenshawy |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Hepatitis
medicine.medical_specialty Cirrhosis medicine.diagnostic_test business.industry Hepatitis C virus Hepatitis C medicine.disease medicine.disease_cause Gastroenterology digestive system diseases Fold change Hepatocellular carcinoma Abdominal ultrasonography Internal medicine medicine MiR-122 business |
| Zdroj: | Medical Journal of Viral Hepatitis. :35-43 |
| ISSN: | 2314-8756 |
| DOI: | 10.21608/mjvh.2019.59524 |
| Popis: | Aim: To explore the potential usefulness of serum microRNA(miR-122) as non-invasive diagnostic marker for hepatitis C virus(HCV)-related hepatocellular carcinoma (HCC). Methods: Thestudy has been conducted on 100 participants and were divided into 4equal groups: Group I; Twenty five normal, healthy individuals. ageand gender-matched healthy volunteers (control group). Group II;Twenty five chronic HCV patients without cirrhosis. Group III;Twenty five HCV related cirrhosis without HCC. Group IV; Twentyfive HCV-related HCC (proved radiologically by abdominal ultrasonography(US) & Triphasic abdominal computed tomography (CT). Allparticipants underwent full clinical assessment and laboratoryinvestigations in addition to the evaluation of the level of serum miR-122 by RT-PCR. Results: microRNA-122 displayed significant foldincrease in expression level in chronic hepatitis group (9.85), and lesssignificant fold increase in cirrhosis group (3.73) and significantfold increase in expression level in HCC group (7.46). Comparingserum miR-122 expression level between different studied groupsdisplayed that, No significant fold change in miR-122 expressionwas found between different groups and that miRNA122 had nosignificant up-regulation in HCC patients in comparison to non-HCCpatients (Hepatitis and Cirrhosis); (P value = 0.682). Specificity &sensitivity was 94% & 16% respectively, with AUROC (0.529).Conclusion: miR-122 could not be used as a biomarker for earlydetection of HCC in HCV related cirrhosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|